Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to ...

Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns over a significant risk linked to the popular drug class: loss of ...

The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly LLY and Novo Nordisk has ... with GLP-1s to possibly enhance weight loss or simply offer an alternative ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug ...

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

(Reuters) - Americans are still eagerly seeking prescriptions for Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO)'s weight-loss and diabetes drugs but cannot always fill them because of supply ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.